Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will also be funded for people with cancer who have high levels of calcium in ...

New Zealand’s medicine-funding agency Pharmac is widening access to a medicine called denosumab for people with osteoporosis.

Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

It's sold under two brand names, Xgeva and Prolia. Denosumab is given by injection every four weeks. It increases bone density by blocking the activity of osteoclasts, a type of cell that breaks down ...

IIT Bombay has developed needle-free shock syringes for painless, safe drug delivery, offering hope for a future without injection-related trauma. Tested on rats, it outperformed traditional needles ...

The Tennessee Department of Correction announced in a brief statement Friday it had "completed its revision of the lethal injection protocol, which will utilize the single drug pentobarbital." ...

But that won’t happen right away. The Tennessee Department of Correction announced in a brief statement Friday it had “completed its revision of the lethal injection protocol, which will utilize the ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, ...